Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Subjects

Subjects :

Immunology
Cell Biology
Hematology
Biochemistry

Details

ISSN :

15280020 and 00064971

Volume :

140

Database :

OpenAIRE

Journal :

Blood

Accession number :

edsair.doi...........04fb86e72e5c0992e5a0b3818bc47b3a

Full Text :

https://doi.org/10.1182/blood-2022-157326